Tumor-associated hepatic microvasculature

The tumor-associated hepatic microvasculature is a specialized vascular network that develops to support the growth and metabolic demands of primary and metastatic liver tumors. In a healthy liver, the microvasculature consists of highly permeable, fenestrated sinusoids; however, during tumorigenesis, these vessels undergo a process known as "capillarization," where endothelial cells lose their fenestrae and develop a continuous basement membrane (Bioulac-Sage et al., 2001). This transformation is driven by the overexpression of pro-angiogenic factors such as Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF), which shift the tumor's blood supply from the portal vein to the hepatic artery (Mazzaferro et al., 2014). This arterialization provides a critical therapeutic window for both systemic anti-angiogenic agents, such as sorafenib and lenvatinib, and locoregional therapies like transarterial chemoembolization (TACE) and selective internal radiation therapy (SIRT) (Llovet et al., 2003). Targeting this microvasculature aims to induce tumor ischemia and disrupt the signaling pathways essential for endothelial cell survival and vessel maintenance. Monitoring changes in this compartment, often through CD34 immunohistochemistry or functional imaging, is vital for assessing treatment efficacy in hepatocellular carcinoma (Cui et al., 2003).

Other names

Hepatic tumor neovasculatureTumor-associated liver microvasculatureAngiogenic liver vesselsCapillarized hepatic sinusoids

Inhibition of pro-angiogenic signaling pathways (VEGFR, PDGFR, FGFR), induction of vascular endothelial cell apoptosis, and physical occlusion or localized irradiation of tumor-feeding arterial vessels.